Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for hepatic fibrosis.

D A Brenner1, J M Alcorn

  • 1Department of Medicine, University of California, San Diego.

Seminars in Liver Disease
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

No perfect therapy exists for liver fibrosis, but emerging treatments show promise. Colchicine is the safest option for untreatable cirrhosis, though more clinical trials are needed for confirmation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signal transduction during liver regeneration.

Journal of gastroenterology and hepatology·2017
Same author

Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study.

Alimentary pharmacology & therapeutics·2016
Same author

Pharmacokinetics and lung and muscle concentrations of tulathromycin following subcutaneous administration in white-tailed deer (Odocoileus virginianus).

Journal of veterinary pharmacology and therapeutics·2015
Same author

Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.

Alimentary pharmacology & therapeutics·2015
Same author

Evidence for a common progenitor of epithelial and mesenchymal components of the liver.

Cell death and differentiation·2013
Same author

Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Alimentary pharmacology & therapeutics·2013
Same journal

Hepatosystemic T cell licensing in MASLD-associated neuroinflammation.

Seminars in liver disease·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
See all related articles

Area of Science:

  • Hepatology
  • Fibrosis Research
  • Pharmacology

Background:

  • Hepatic cirrhosis fibrogenesis lacks established therapies.
  • Ideal antifibrotic agents must be liver-specific, target extracellular matrix, and be non-toxic.
  • Current therapeutic options do not meet these ideal criteria.

Purpose of the Study:

  • To review emerging therapies for hepatic fibrosis.
  • To evaluate the safety and efficacy of potential antifibrotic agents.
  • To identify the most promising therapeutic strategies for clinical development.

Main Methods:

  • Literature review of potential antifibrotic agents.
  • Assessment of agent specificity, liver-targeting capabilities, and toxicity profiles.
  • Evaluation of the developmental stage of various therapeutic candidates.

Related Experiment Videos

Main Results:

  • No single agent currently meets all criteria for a perfect antifibrotic therapy.
  • Colchicine demonstrates acceptable safety for use in specific patient populations, pending further trials.
  • Other agents like collagen propeptides, prolyl 4-hydroxylase inhibitors, proline analogues, prostaglandins, malotilate, and gamma-interferon require further development or clinical validation.

Conclusions:

  • Colchicine is a potential candidate for managing untreatable hepatic cirrhosis, but requires more clinical trial validation.
  • Significant further research and development are necessary for other promising antifibrotic agents.
  • The development of effective therapies for hepatic fibrosis remains an ongoing challenge requiring rigorous investigation.